TB-500 Canada: Research Identity, Vial Labels & COA Checklist

Looking for TB-500 research material in Canada? Start with the identity on the document, not the name on the vial. Compare the stated sequence, listed quantity, lot-specific analytical evidence and Canadian delivery terms. A price comparison is only useful once you know the listings describe the same material.

This guide is for research procurement and document review. It does not recommend personal use, treatment, dosing or administration.

TB-500 Canada: the quick comparison checklist#

Before comparing two listings, record these fields side by side:

• Identity: exact sequence, terminal modifications and whether the document describes a fragment or full-length thymosin beta-4.
• Variant: stated amount per vial, number of vials and whether the material is a standalone compound or a blend.
• Lot: the batch identifier on the listing, vial and certificate of analysis.
• Evidence: test date, laboratory identity, analytical method and any available chromatogram or mass-spectrum results.
• Fulfilment: dispatch country, shipping charge, carrier, handling time and the process for a missing or mismatched document.

Affiliation disclosure: Northern Compound is affiliated with LynxLabs. The LynxLabs TB-500 product record is one listing to examine, not an independently certified recommendation. Apply the same checks to it as to any other vendor. If its lot or identity evidence is missing or inconsistent, ask for clarification rather than treating the link as proof.

For a document-first walkthrough, use the TB-500 lot and COA checklist. This is an affiliated resource, not laboratory verification of a vial.

What does TB-500 mean in the research literature?#

The most useful starting point is an analytical paper rather than a vendor description. Esposito and colleagues, 2012 reported detecting and identifying the N-terminal acetylated 17–23 fragment of human thymosin beta-4, Ac-LKKTETQ, in a formulation called TB-500. The researchers used high-performance liquid chromatography and high-resolution mass spectrometry, and also synthesized the fragment.

The numbers 17–23 are positions in the parent sequence. They do not mean the fragment has 17 amino acids. The NIH/NCATS substance record lists the seven-residue LKKTETQ sequence and the acetylated fragment name.

That paper establishes what was identified in the tested formulation. It does not establish what every current product sold under the same commercial name contains. A catalogue label, a chemical registry entry and an analysis of the supplied lot are different kinds of evidence.

Editorial correction, October 6, 2026: an earlier version of this guide repeatedly described TB-500 as a 17-amino-acid fragment. That was incorrect. We have replaced that description and removed unsupported protocol, product-certification and legal assurances. The original publication date is preserved above.

Fragment or full-length thymosin beta-4: why the distinction matters#

Do not transfer a study's conclusions to a product simply because both descriptions mention thymosin beta-4. Start with the paper's methods: what exact material was tested, how was it characterized, and what endpoint was measured?

Then compare those details with the product record. If a listing and COA use different names or describe different sequences, stop the comparison and ask the vendor to reconcile them. A purity percentage cannot resolve an identity mismatch.

This guide does not assess a product's therapeutic effects. A paper on a related material is not evidence that a commercial vial is suitable for use in people or animals.

How to read a TB-500 certificate of analysis#

1. Match the document to the supplied lot#

Save the listing and COA together. Record the product name, variant, lot number, report identifier and test date. If the webpage says one batch and the document says another, mark the match as unresolved.

An authentic certificate for an older lot may still be a valid historical document. It is not automatically evidence for a newly supplied lot. Ask for the matching report without assuming the older certificate is fake.

2. Separate purity from identity#

HPLC peak-area purity describes a result under a particular analytical method. It should not be read as a standalone confirmation of sequence, quantity, sterility or safety.

For identity review, look for the stated material, expected mass, observed result and method. Ask the laboratory or vendor what the method can distinguish. A mass result alone may not resolve every possible structural or sequence ambiguity.

3. Separate vial quantity from purity#

The amount printed on a vial and the percentage on a chromatogram are not interchangeable. Ask whether quantity was measured, what was measured, and whether the result refers to peptide content or another reporting basis.

Do not calculate a supposedly verified amount from a label and a purity percentage alone. If the quantity evidence is absent, record it as not provided, not as a failed result and not as a confirmed amount.

4. Keep the original evidence#

Retain the original certificate, date accessed and correspondence clarifying discrepancies. Check whether the laboratory offers report verification through a published contact or verification service. Do not assume that a logo or a polished PDF proves authenticity.

Our COA request email template helps keep that request specific. Ask for the exact lot and variant rather than a generic statement that a vendor's products are tested.

Comparing TB-500 vial listings in Canada#

A low price means little if the listings differ in identity, stated amount, vial count or document coverage. Keep those differences visible instead of forcing every listing into one ranking.

For each candidate, save:

1. The exact listing URL and date checked.
2. The material description and variant.
3. The CAD price and whether it is per vial or per package.
4. Shipping charges and any order threshold.
5. The lot-specific evidence that was actually available.
6. Questions still awaiting an answer.

Availability and shipping terms can change. Confirm them on the current listing before relying on an older article or comparison. Do not interpret a domestic dispatch address as evidence of Canadian manufacture, laboratory accreditation or regulatory approval.

For the broader process, see the Canadian research-material buyer's guide. Keep procurement decisions within your organization's approval and compliance process.

Questions to send before proceeding#

Please confirm the exact peptide sequence and terminal modifications for this TB-500 variant. Which lot would be supplied? Can you provide the corresponding certificate, analytical methods and any identity or quantity results? Please explain any difference between the product label and the report, and confirm the dispatch location and current shipping terms.

A clear answer should resolve the specific mismatch. A repeated purity claim, generic certificate or unrelated publication does not answer a lot-identity question.

Research-use labels and Canadian requirements#

A research-use-only label is not a regulatory approval or a blanket exemption. This guide does not determine whether a proposed purchase, import or use is lawful. Ask your institution's procurement and compliance staff to evaluate the intended work and consult current Health Canada guidance where relevant.

Domestic shipping can change logistics. It does not eliminate all legal, quality or handling risks.

Sources and scope#

• Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500. Drug Testing and Analysis. 2012;4(9):733–738. DOI: 10.1002/dta.1402. Analytical identification, not a product endorsement or clinical recommendation.
• NIH/NCATS GSRS. TB-500 substance record. Identity reference, not evidence for any particular vendor's lot.
• Health Canada. Drugs and health products. Official starting point for current guidance; this article is not legal advice.